Unlock instant, AI-driven research and patent intelligence for your innovation.
Composition with losartan potassium and gliclazide and preparation method thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A kind of technology of losartan potassium and composition, applied in the field of losartan potassium and gliclazide composition and preparation thereof
Inactive Publication Date: 2019-03-08
CHENGDU HENGRUI PHARMA
View PDF0 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0004] Losartan potassium and gliclazide form a compound preparation, which can exert the beneficial effect of losartan potassium on the treatment of hypertension combined with diabetes. The two synergistically exert the effect of lowering blood pressure and blood sugar, but there is no corresponding composition in the prior art can achieve the above therapeutic effect
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0028] A composition of losartan potassium and gliclazide and its preparation method:
[0030] Preparation method: Take 4.8g of precrossed starch and add 55.2g of water to make 60g of precrossed starch slurry with a concentration of 8% as a binder, add 40g of losartan potassium, 40g of microcrystalline cellulose, 55.2g of precrossed starch In the mixture composed of starch, make soft material and then granulate with 20-mesh sieve, dry at 40°C until the water content is 1%, and then granulate with 30-mesh sieve, then mix with 40g gliclazide, 20g anhydrous calcium hydrogen phosphate, 4g Silicon dioxide and 2 g of magnesium stearate were uniformly mixed together and then pressed into tablets to obtain losartan potassium and gliclazide compos...
Embodiment 2
[0032] A composition of losartan potassium and gliclazide and its preparation method:
[0034] Preparation method: Take 10g of precrossed starch and add 90g of water to prepare 100g of precrossed starch slurry with a concentration of 10% as a binder, and add it to a mixture consisting of 60g of losartan potassium, 60g of microcrystalline cellulose and 70g of precrossed starch. In the mixture, the soft material is granulated with a 30-mesh sieve, dried at 70°C until the water content is 2%, and then granulated with a 30-mesh sieve, and then mixed with 80g gliclazide, 40g anhydrous calcium hydrogen phosphate, and 8g silicon dioxide , 3g of magnesium stearate were uniformly mixed together and then pressed into tablets to obtain losartan pota...
Embodiment 3
[0036] A composition of losartan potassium and gliclazide and its preparation method:
[0037] The composition includes: 50g of losartan potassium, 40g of gliclazide, 50g of microcrystalline cellulose, 25g of anhydrous calcium hydrogen phosphate, 65g of precrossified starch, 6g of silicon dioxide, and 2g of magnesium stearate;
[0038] Preparation method: Take 9.6g of precrossed starch and add 70.4g of water to prepare 80g of precrossed starch slurry with a concentration of 12% as a binder, add 45g of losartan potassium, 50g of microcrystalline cellulose, 55.4g of precrossed starch In the mixture composed of starch, make soft material and then granulate with 24 mesh sieve, dry at 50°C until the water content is 3%, and then granulate with 30 mesh sieve, then mix with 40g gliclazide, 25g anhydrous calcium hydrogen phosphate, 6g Silicon dioxide and 2 g of magnesium stearate were uniformly mixed together, and then directly compressed into tablets to obtain tablets of the composit...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
technical field [0001] The invention relates to a pharmaceutical composition for treating hypertension combined with diabetes, in particular to a composition of losartan potassium and gliclazide and a preparation method thereof. Background technique [0002] LosartanPotassium Tablets, the world's first angiotensin IIreceptorantagonist (AIIA) for the treatment of hypertension, was officially launched in China in 1998. The results of a number of large-scale clinical studies have shown that the use of losartan can effectively lower blood pressure, reduce cardiovascular risk, and delay end-stage renal disease. The RENAAL study showed that losartan can significantly reduce the risk of ESRD by 28%; the LIFE study showed that losartan Potassium significantly reduced the primary composite cardiovascular endpoint by 13%. Big data analysis shows that angiotensin receptor blocker (ARB) is the drug of choice for the treatment of hypertension complicated with diabetes. Losartan potas...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.